Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

thAnnual Ophthalmology Virtual Conference on August 13, 2025. Sylvia Cheung, Oculis’ Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ETSnehal Shah, Oculis’ President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Assets for Retinal Disorders. The panel discussion will also be made available via webcast for replay. Links to access the corporate...

ZUG, 12/08/2025 (informazione.news - comunicati stampa - salute e benessere)

Annual Ophthalmology Virtual Conference on August 13, 2025.

Links to access the corporate update presentation and the panel discussion will be posted to Oculis’ website on the Events & Presentation page under the Investors & Media section.

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com 

ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com